WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Close this folderRegulatory actions
View the documentAlbumin (human): batches withdrawn: increase in aluminium level: Germany
View the documentAlfalfa products: caution label: Malaysia
View the documentAmineptine: marketing authorization suspended: drug abuse and dependence: France
View the documentAstemizole: OTC formulations withdrawn: UK
View the documentCisapride: restricted indications: Ireland
View the documentDronabinol: proposed reclassificaion from Schedule II to Schedule III of the US Controlled Substances Act: USA
View the documentEntacapone: revised product information: caution concerning use: EMEA
View the documentFurazolidone: withdrawn: Yemen
View the documentGinkgo biloba parenteral infusion formulation: suspension further extended: Germany
View the documentIsotretinoin: revised prescribing information: depression: Ireland
View the documentKaolin and pectin suspension: withdrawn: Yemen
View the documentLevocarnitine: revised data sheet: seizures: USA
View the documentLoratadine/pseudoephedrine sulfate: reformulated: UK
View the documentMetamizole sodium: withdrawn due to agranulocytosis: Yemen
View the documentMethadone mixture: child-resistant packaging recommended: Germany
View the documentMethylrosanilinium chloride (Gentian violet): withdrawn: Malaysia
View the documentMontelukast: revised data sheet: eosinophilia: UK
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsGeneral information
Open this folder and view contentsMedication errors
Open this folder and view contentsVeterinary medicine
 

Albumin (human): batches withdrawn: increase in aluminium level: Germany

Germany. The Paul-Ehrlich-Institut has recalled certain batches of human albumin products (Human Albumin 20%, Human Albumin 20% Immuno, Human Albumin Immuno 20%, Human Albumin 25% Immuno) with effect from 30 September 1998, including batches that have exceeded 12 months of shelf-life.

This action was taken after quality assurance tests showed that the aluminium content of these batches had exceeded the maximum level of 200 micrograms/L. This could result in adverse effects especially in neonates and dialysis patients because of deposits in the brain and bones.

Similar actions have been taken in Belgium and Italy.

[See also Pharmaceuticals Newsletter Nos. 9 & 10, September & October 1998]

Reference: Pharmazeutisches Zeitung 143(43): 3746 (1998).

to previous section to next section
 

Last updated: May 3, 2013